Goldman Sachs just refreshed its lists of top global stock picks, adding some and removing others. The investment bank's "Conviction List - Directors' Cut" aims to offer investors a "curated and active" list of 15 to 25 buy-rated stocks. The stocks are selected by a subcommittee designated by the bank's Investment Review Committee for each region.
Samsung Biologics Goldman likes South Korean biotechnology company Samsung Biologics, which it says is "set to capitalize on growing demand for biologics CDMOs via its build-out of world-leading capacity." Other merits of the company include its "competitive pricing strategy," Goldman analyst Ziyi Chen wrote in a May 2 note on the bank's Asia-Pacific list.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »
Source: CNBC - 🏆 12. / 72 Read more »
Source: CNBC - 🏆 12. / 72 Read more »